Last reviewed · How we verify
TRILACICLIB
At a glance
| Generic name | TRILACICLIB |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2021 |
Approved indications
Common side effects
- Fatigue
- Hypocalcemia
- Hypokalemia
- Hypophosphatemia
- Aspartate aminotransferase increased
- Headache
- Pneumonia
Key clinical trials
- Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid Tumors (PHASE1)
- Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer (PHASE3)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer (PHASE2)
- the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib (PHASE2)
- Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer) (PHASE2)
- Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC (PHASE2)
- Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRILACICLIB CI brief — competitive landscape report
- TRILACICLIB updates RSS · CI watch RSS